Stock A199800 TOOLGEN INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

News ToolGen Incorporated

Equities

A199800

KR7199800004

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
61,100 KRW +0.66% Intraday chart for ToolGen Incorporated +1.66% -12.96%
2023 ToolGen Incorporated announced that it has received KRW 33 billion in funding CI
2023 ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
The 2023 Pharmaceutical Patent Review
AQ
DCC Insights Issue 19
AQ
ToolGen Incorporated announced that it has received KRW 33 billion in funding
CI
ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding
CI
ToolGen Incorporated v Fisher (No 2) – Lessons In Entitlement To Priority From The Australian Federal Court
AQ
Toolgen Leads Development of Numerous Cutting-Edge Genome Editing Techniques
CI
ToolGen Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022
CI
ToolGen Incorporated(KOSDAQ:A199800) added to S&P Global BMI Index
CI
MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc
CI
ToolGen Incorporated has completed an IPO in the amount of KRW 70 billion.
CI
ToolGen Incorporated has filed an IPO.
CI
ToolGen Incorporated announced that it has received KRW 10.0000004 billion in funding from Genexine, Inc.
CI
ToolGen Incorporated announced that it expects to receive KRW 10.0000004 billion in funding from Genexine, Inc.
CI
Genexine, Inc. cancelled the acquisition of ToolGen Incorporated.
CI
Genexine, Inc. agreed to acquire ToolGen Incorporated for approximately KRW 350 billion.
CI
ToolGen, Inc., Demonstrates CRISPR/Cas9 Gene Editing Improves Anti-Tumor Activity of Human Car-T Cells
CI
Monsanto Company and ToolGen, Inc. Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of Innovation for Farmers
CI
ToolGen, Inc. Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System in vivo Genome Editing
CI
ToolGen Incorporated announced that it has received KRW 10.0223744 billion in funding
CI
ToolGen Incorporated announced that it expects to receive KRW 10.0223744 billion in funding
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A199800 Stock
  4. News ToolGen Incorporated